Business & Finance
Business and Finance
Business and Finance
Fri, October 28, 2011 
CARSON CITY, Nev.--([ BUSINESS WIRE ])--XYTOS, Inc. (the "Company") (OTC: XYTS); In an effort to keep the shareholders informed XYTOS offers the following update:
After months of Due Diligence on the company by the German Regulators, XYTOS was cleared to start trading in Germany on September 12, 2011. Unfortunately there were additional unexpected delays while the company worked to get the German Shares available for electronic settlement through the Clearstream Clearing System. XYTOS is now pleased to announce that as of earlier this week all necessary steps have been completed and the company can now move forward with plans to establish an Actively Trading Market for our Euro Shares in Germany.
Additionally, in line with company planning, the completion of this process in Germany immediately opened the door for the companyas European Investors to join our U.S. Shareholders in support of the company in the U.S. Market.
XYTOS appreciates the support of our loyal shareholders and for this reason every calculated step by the company is done with the shareholders in mind. With this said, XYTOS is focused on creating a strong stock price and shareholder base, and as the companyas Bio-Medical future unfolds through upcoming news announcements, shareholders will clearly see the focused directions that management has put in place to make XYTOS a Global Leader in the Introduction of Advance Medical Procedures.
Further, as XYTOS continues to grow in the Capital Markets on two continents; and as the company continues to implement simple supply side economics by limiting the number of shares in the market, management feels that we will bring the stock price in line with other companies in our sector that have far less technology to offer. Additionally, with XYTOS working in new areas of Advanced Medical Procedures, it must be understood that the company may occasionally encounter unexpected delays as it takes Regulators (both Medical and Financial) time to understand certain aspects of the companyas Advanced Bio-Medical Technologies. Any such delay on a specific Bio-Medical Technology should appear seamless to shareholders since the company has multiple technologies to introduce.
Finally, upcoming announcements will further detail the progress the company has made in setting a solid financial foundation for the companyas future. This solid foundation will allow the company to then start announcing details of Advance Medical Procedures that the company will be introducing to the Global Medical Community.
As the company brings in new shareholders, as always, we would like those shareholders that are looking for periodic updates, via email, to opt in at [ shareholders@xytos.com ].
XYTOS, working at the forefront of the "Science of Medicine," is a Bio-Medical Technologies Company concentrating on the Research, Development, and Introduction of Next Generation Medicine and Medical Procedures in the areas of Stem Cell Therapies, Tissue Engineering, Cellular Medicine, and Cancer.
On behalf of the Board of Directors of: XYTOS Inc.
(Contact: [ info@xytos.com ]) Telephone: 702-421-5206
